The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Jinarc tolvaptan | Otsuka Pharmaceutical Netherlands B.V. | Polycystic Kidney, Autosomal Dominant | 🇪🇺 EU 2015-05-27 | Order → |
| Synjardy empagliflozin;metformin | Boehringer Ingelheim | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2015-05-27 | Order → |
| Voriconazole Hikma (previously Voriconazole Hospira) voriconazole Generic | Hikma Farmaceutica (Portugal) S.A. | Bacterial Infections and Mycoses; Aspergillosis; Candidiasis | 🇪🇺 EU 2015-05-27 | Order → |
| Zykadia ceritinib | Novartis Europharm Limited | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2015-05-06 | Order → |
| Ristempa pegfilgrastim Additional monitoring | Amgen Europe B.V. | 🇪🇺 EU 2015-04-13 | Order → | |
| Dutrebis lamivudine;raltegravir potassium | Merck Sharp Dohme Limited | HIV Infections | 🇪🇺 EU 2015-03-26 | Order → |
| Mysimba naltrexone;bupropion Additional monitoring | Orexigen Therapeutics Ireland Limited | Obesity; Overweight | 🇪🇺 EU 2015-03-26 | Order → |
| Quinsair levofloxacin | Chiesi Farmaceutici S.p.A | Cystic Fibrosis; Respiratory Tract Infections | 🇪🇺 EU 2015-03-25 | Order → |
| Kengrexal cangrelor Additional monitoring | Chiesi Farmaceutici S.p.A. | Acute Coronary Syndrome; Vascular Surgical Procedures | 🇪🇺 EU 2015-03-23 | Order → |
| Saxenda liraglutide | Novo Nordisk A/S | Obesity; Overweight | 🇪🇺 EU 2015-03-23 | Order → |
| Sivextro tedizolid phosphate | Merck Sharp & Dohme B.V. | Soft Tissue Infections; Skin Diseases, Bacterial | 🇪🇺 EU 2015-03-23 | Order → |
| Ikervis ciclosporin | Santen Oy | Corneal Diseases | 🇪🇺 EU 2015-03-19 | Order → |
| Raplixa human fibrinogen;human thrombin Additional monitoring | Mallinckrodt Pharmaceuticals Ireland Limited | Hemostasis, Surgical | 🇪🇺 EU 2015-03-19 | Order → |
| Tenkasi (previously Orbactiv) oritavancin | Menarini International Operations Luxembourg S.A. | Soft Tissue Infections; Skin Diseases, Bacterial | 🇪🇺 EU 2015-03-19 | Order → |
| Vantobra tobramycin | Pari Pharma GmbH | Cystic Fibrosis; Respiratory Tract Infections | 🇪🇺 EU 2015-03-18 | Order → |
| Tasermity sevelamer hydrochloride | Genzyme Europe BV | Hyperphosphatemia; Renal Dialysis | 🇪🇺 EU 2015-02-25 | Order → |
| Xadago safinamide | Zambon SpA | Parkinson Disease | 🇪🇺 EU 2015-02-23 | Order → |
| Xydalba dalbavancin | AbbVie Deutschland GmbH & Co. KG | Soft Tissue Infections; Skin Diseases, Bacterial | 🇪🇺 EU 2015-02-19 | Order → |
| Clopidogrel ratiopharm clopidogrel Generic | Teva B.V. | Myocardial Infarction; Acute Coronary Syndrome; Peripheral Vascular Diseases; Stroke | 🇪🇺 EU 2015-02-18 | Order → |
| Holoclar ex vivo expanded autologous human corneal epithelial cells containing stem cells ATMPAdditional monitoring | Holostem s.r.l. | Stem Cell Transplantation; Corneal Diseases | 🇪🇺 EU 2015-02-17 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.